Author: Merzon, Eugene; Green, Ilan; Vinker, Shlomo; Golanâ€Cohen, Avivit; Gorohovski, Alessandro; Avramovich, Eva; Frenkelâ€Morgenstern, Milana; Magen, Eli
Title: The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVIDâ€19 infection Cord-id: 5utq6bzk Document date: 2021_2_23
ID: 5utq6bzk
Snippet: Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVIDâ€19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVIDâ€19 susceptibility and disease duration. We conducted a retrospective populationâ€based crossâ€sectional study, utilizing data from the Leumit Health Services database. The proportio
Document: Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVIDâ€19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVIDâ€19 susceptibility and disease duration. We conducted a retrospective populationâ€based crossâ€sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVIDâ€19â€positive group, as compared to the COVIDâ€19â€negative group (73 (11.03 %) vs. 1548 (15.77%); p=0.001). Aspirin use was associated with lower likelihood of COVIDâ€19 infection, as compared to nonâ€users (adjusted OR 0.71 (95% CI, 0.52 to 0.99; p=0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; p<0.001), presented a lower BMI (28.77±5.4 vs. 30.37±4.55; p<0.0189) and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%) and COPD (11, 15.07%) than showed the aspirin nonâ€users (151, 25.64%, p<0.001; 130, 22.07%, p<0.001; and 43, 7.3%, p=0.023, respectively). Moreover, COVIDâ€19 disease duration (considered as the time between the first positive and second negative COVIDâ€19 RTâ€PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonâ€users (19.8±7.8 vs. 21.9± 7.9 p= 0.045). Among hospitalized COVIDâ€positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (p=0.449). In conclusion, we observed inverse association between the likelihood of COVIDâ€19 infection, disease duration and mortality and aspirin use for primary prevention.
Search related documents:
Co phrase search for related documents- ace inhibitor and adaptive innate: 1
- ace inhibitor and adaptive innate immunity: 1
- ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
- ace inhibitor and logistic regression analysis: 1
- ace inhibitor and lung disease: 1
- acetylsalicylic acid and acute coronary syndrome: 1, 2
- acetylsalicylic acid and logistic regression: 1, 2
- acetylsalicylic acid and logistic regression analysis: 1, 2
- acetylsalicylic acid and low dose aspirin: 1
- acute coronary syndrome and adaptive innate: 1
- acute coronary syndrome and adaptive innate immunity: 1
- acute coronary syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute coronary syndrome and logistic regression analysis: 1, 2, 3, 4
- acute coronary syndrome and low dose aspirin: 1
- adaptive innate and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive innate and logistic regression analysis: 1, 2, 3
- adaptive innate and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- adaptive innate immunity and logistic regression: 1, 2, 3
- adaptive innate immunity and logistic regression analysis: 1
Co phrase search for related documents, hyperlinks ordered by date